Eritrea
Tuberculosis profile
| High HIV burden |
Population  2013 6.3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (0.64–1.8) 20 (10–29)
Mortality (HIV+TB only) 0.12 (0.083–0.15) 1.8 (1.3–2.4)
Prevalence  (includes HIV+TB) 9.7 (5–16) 153 (78–252)
Incidence  (includes HIV+TB) 5.8 (4.6–7.3) 92 (72–116)
Incidence (HIV+TB only) 0.36 (0.28–0.45) 5.6 (4.4–7.1)
Case detection, all forms (%) 49 (39–62)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
34 (2–96) 48 (0–95)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 772   121
Pulmonary, clinically diagnosed 1 039   0
Extrapulmonary 928   0
       
Total new and relapse 2 860    
Previously treated, excluding relapses 117    
Total cases notified 2 977    
Among 2 739 new cases:
596 (22%) cases aged under 15 years;
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 22 (9%) 22
Laboratory-confirmed RR-/MDR-TB cases     17
Patients started on MDR-TB treatment     35
TB/HIV 2013 Number (%)
TB patients with known HIV status 2 224 (75)
HIV-positive TB patients 136 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 17 (13)
HIV-positive TB patients on antiretroviral therapy (ART) 23 (17)
HIV-positive people screened for TB 522  
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 87
Previously treated cases registered in 2012 72
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 45
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.8
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 5
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 4.6
% Funded domestically <1%
% Funded internationally 99%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-31 Data: www.who.int/tb/data